;
Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • ShK-186: Phase Ib started

    Airmid Inc., Redwood City, Calif. Kineta Inc., Seattle, Wash. Product: ShK-186 Business: Autoimmune Molecular target: Potassium channel Kv1.3 (KCNA3) Description: Synthetic peptide that inhibits potassium channel Kv1.3…

    Published on 10/20/2014
  • Simeprevir: Phase II started

    Medivir AB (SSE:MVIR B), Huddinge, Sweden Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Simeprevir (Sovriad, Galexos, Olysio) (TMC435) (formerly TMC435350) Business: Infectious Molecular target: HCV NS3/4A …

    Published on 10/20/2014
  • VAL201: Phase I/II start

    ValiRx plc (LSE:VAL), London, U.K. Cancer Research UK, London, U.K. Product: VAL201 Business: Cancer Molecular target: Src Description: Src inhibitor Indication: Treat prostate cancer Endpoint: Safety Status: Phase I/II…

    Published on 10/20/2014
  • VSV-EBOV: Phase I started

    NewLink Genetics Corp. (NASDAQ:NLNK), Ames, Iowa Product: VSV-EBOV Business: Infectious Molecular target: NA Description: Recombinant vesicular stomatitis virus (rVSV) vaccine expressing an Ebola virus protein …

    Published on 10/20/2014
  • XOMA 358: Phase I started

    Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Product: XOMA 358 Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR) Description: Allosteric human mAb that binds to insulin receptor (INSR) Indication: …

    Published on 10/20/2014
  • Zybrestat fosbretabulin: Phase Ib/II started

    OxiGene Inc. (NASDAQ:OXGN), South San Francisco, Calif. Product: Zybrestat fosbretabulin (Combretastatin A4P) Business: Cancer Molecular target: Tubulin Description: A4 prodrug phosphatase-activated tumor vascular …

    Published on 10/20/2014
  • 18-methoxycoronaridine: Phase I started

    Hebron Farmaceutica S.A, Caruaru, Brazil Savant HWP Inc., San Carlos, Calif. Product: 18-methoxycoronaridine (18-MC) Business: Infectious Molecular target: Nicotinic acetylcholine receptor alpha(3)beta(4) Description: …

    Published on 10/13/2014
  • AeroVanc: Completed Phase II enrollment

    Savara Inc., Austin, Texas Product: AeroVanc (SAV005) Business: Infectious Molecular target: NA Description: Inhaled dry powder formulation of vancomycin in a capsule-based inhaler Indication: Treat methicillin-…

    Published on 10/13/2014
  • ALN-AS1: Clinical trial started

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Product: ALN-AS1 Business: Endocrine/Metabolic Molecular target: Aminolevulinate synthase-1 (ALAS-1) Description: Subcutaneous RNAi therapeutic targeting …

    Published on 10/13/2014
  • Arzerra ofatumumab: Phase III started

    Genmab A/S (CSE:GEN; OTCBB:GMXAY), Copenhagen, Denmark GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Arzerra ofatumumab (HuMax-CD20) Business: Autoimmune Molecular target: CD20 Description: Human mAb …

    Published on 10/13/2014
  • Dexamethasone-loaded punctum plug: Completed Phase III enrollment

    Ocular Therapeutix Inc. (NASDAQ:OCUL), Bedford, Mass. Product: Dexamethasone-loaded punctum plug (OTX-DP) Business: Neurology Molecular target: NA Description: Hydrogel-based punctum plug that delivers sustained- and …

    Published on 10/13/2014
  • Estradiol VagiCap: Phase III started

    TherapeuticsMD Inc. (NYSE-M:TXMD), Boca Raton, Fla. Product: Estradiol VagiCap (TX-004HR) (formerly TX 12-004-HR) Business: Endocrine/Metabolic Molecular target: NA Description: 17-beta estradiol using a VagiCap softgel…

    Published on 10/13/2014
  • Gevokizumab: Phase III started

    Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Servier, Neuilly-sur-Seine, France Product: Gevokizumab (S 78989, XOMA 052) Business: Inflammation Molecular target: Interleukin-1 (IL-1) beta Description: Humanized IgG2 mAb …

    Published on 10/13/2014
  • IBI-10090: Phase III ongoing

    Icon Bioscience Inc., Sunnyvale, Calif. Product: IBI-10090 Business: Ophthalmic Molecular target: NA Description: Sustained-release formulation of anti-inflammatory agent dexamethasone delivered using Verisome …

    Published on 10/13/2014
  • Masican masitinib: Phase III ongoing

    AB Science S.A. (Euronext:AB), Paris, France Product: Masican masitinib (AB1010) Business: Dermatology Molecular target: Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) Description: Stem cell …

    Published on 10/13/2014
  • MiR-21: Clinical trial started

    Regulus Therapeutics Inc. (NASDAQ:RGLS), San Diego, Calif. Product: MiR-21 (anti-miR-21) (RG-012) (formerly antagomir-21) Business: Renal Molecular target: MicroRNA-21 (miR-21) Description: Antisense oligonucleotide …

    Published on 10/13/2014
  • NBI-98854: Phase Ib started

    Neurocrine Biosciences Inc. (NASDAQ:NBIX), San Diego, Calif. Product: NBI-98854 Business: Neurology Molecular target: Vesicular monoamine transporter 2 (VMAT2) (SLC18A2) Description: Selective vesicular monoamine …

    Published on 10/13/2014
  • RTA 408: Phase II start

    Reata Pharmaceuticals Inc., Irving, Texas Product: RTA 408 Business: Endocrine/Metabolic Molecular target: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) (NRF2); NF-kappa B (NF-kB) Description: Oleanane …

    Published on 10/13/2014
  • RTA 408: Phase II start

    Reata Pharmaceuticals Inc., Irving, Texas Product: RTA 408 Business: Neurology Molecular target: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) (NRF2); NF-kappa B (NF-kB) Description: Oleanane triterpenoid that …

    Published on 10/13/2014
  • Simdax levosimendan: Phase III started

    Orion Corp. (HSE:ORNAV; HSE:ORNBV), Espoo, Finland Tenax Therapeutics Inc. (NASDAQ:TENX), Morrisville, N.C. Product: Simdax levosimendan Business: Cardiovascular Molecular target: Potassium channel Description: Calcium …

    Published on 10/13/2014
  • Subcutaneous beloranib: Completed Phase IIa enrollment

    Zafgen Inc. (NASDAQ:ZFGN), Cambridge, Mass. Chong Kun Dang Pharmaceutical Corp. (KSE:001630), Seoul, South Korea Product: Subcutaneous beloranib (ZGN-440, CKD-732) Business: Endocrine/Metabolic Molecular target: …

    Published on 10/13/2014
  • TD139: Phase I/IIa started

    Galecto Biotech AB, Copenhagen, Denmark Product: TD139 Business: Pulmonary Molecular target: Galectin-3 (LGALS3) Description: Galectin-3 (LGALS3) inhibitor Indication: Treat idiopathic pulmonary fibrosis (IPF) Endpoint:…

    Published on 10/13/2014
  • AKB-6548: Phase II started

    Akebia Therapeutics Inc. (NASDAQ:AKBA), Cambridge, Mass. Product: AKB-6548 Business: Hematology Molecular target: Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) (EGLN) Description: Oral hypoxia-inducible factor …

    Published on 10/6/2014
  • Arhalofenate: Completed Phase IIb enrollment

    CymaBay Therapeutics Inc. (NASDAQ:CBAY), Newark, Calif. Product: Arhalofenate (MBX-102) Business: Endocrine/Metabolic Molecular target: Solute carrier family 22 organic anion urate transporter member 12 (SLC22A12) (…

    Published on 10/6/2014
  • Benzhydrocodone/acetaminophen: Clinical trial started

    KemPharm Inc., Coralville, Iowa Product: Benzhydrocodone/acetaminophen (KP201) Business: Neurology Molecular target: NA Description: Abuse-deterrent formulation of benzhydrocodone, a hydrocodone prodrug, and …

    Published on 10/6/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993